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ABSTRACT 
OBJECTIVE: To determine if Tranexamic Acid effectively and safely reduce menstrual 
blood loss (MBL) in women with Menorrhagia or IUD induced MBL? 
STUDY DESIGN: Review of all English language primary randomized controlled trial 
stndies published in 2006, 2007, and 2009. 
DATA SOURCES: Randomized Controlled Trials comparing Tranexamic Acid (TA) to 
placebo were found using MEDLINE, OVID, and COCHRANE databases 
OUTCOME MEASURED: Each of the three trials measured levels of reducing 
menstrual blood loss in women with menorrhagia or IUD induced MBL by using 4 
instruments for assessing QOL: Health-Related QOL instrument, Short Form-36, 
Center for Epidemiologic Studies Depression Scale, Modified Ruta Menorrhagia 
Severity Scale. MBL and prevention of Menorrhagia measured by pictorial blood loss 
assessment chart (PBAC), Hemoglobin count and the number of sanitary protection 
soiled with blood (Pads or Tampons). Subjective systematic relief (safety 7 efficacy)-
Visual Analog Scale (VAS), student T test, 2 way ANOVA 
RESULTS: All three randomized controlled trials included in this review found that 
TA more effectively and safely reduced MBL than the placebo groups. In all three 
trials, the most common adverse effect experienced in the treatment groups in both 
Kripilani and Kouides was headache. 
CONCLUSIONS: The results of RCT's reviewed demonstrate that TA dose taking 
daily is effective in reducing MBL in women with Menorrhagia or IUD induced MBL. 
Further research with TA is needed to determine the optimal dosage for maximizing 
efficacy and minimizing adverse effects. 
KEY WORDS: Tranexamic Acid, Transamin, Menorrhagia, Quality oflife, Menstrual 
Blood Loss, IUD Induced MBL 
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INTRODUCTION 
Menorrhagia is defined as women experiencing heavy or prolonged menstrual with blood 
lost of 5-6 tablespoons (about 80 milliliters +) of blood during their menstrual period usually 
from 7-21 days. A nonnal female usually loses 2 to 3 tablespoons (35 to 40 milliliters) of blood 
over three to seven days. LosiIig a lot of blood during the menstrual period can cause medical 
problems like anemia and can also be caused by many medical conditions. It is a common 
clinical problem, reported by 5-10% of women of reproductive age. Women with menorrhagia 
traditionally undergo frequent intensive investigation, yet 50% of these cases, the cause are never 
identified. The optimal management of women with menorrhagia has not been detennined. 
Currently, there are many effective treatments but with adverse reactions or side effects. 
Approximately 35% of women with dysfunctional uterine bleeding (DUB) will under go 
hysterectomy, which is the definitive cure for menorrhagia but, associated operative and long 
tenn morbidity and rarely mortality for essentially a benign condition, especially in younger 
women where hysterectomy is inappropriate, those nearing menopause, this is not considered 
insiguificant. Thus, drug therapy should be the first line of treatment before turning to surgery. 
Currently, Chinese women most popularly use of contraception in China is intrauterine device 
(IUD); however with so many adverse effects, especially bleeding, it is essential to prevent IUD 
induced menstrual blood loss (MBL). 
Approximately 7 million women are affected. 1120 women aged 25- 44 years will visit 
her general practitioner each year requesting treatment for heavy periods. 71 % of women do not 
discuss their menorrhagia symptoms with their physician and do not receive treatment. Heavy 
periods can be debilitating, can lead to social embarrassment and medical problems, symptoms 
such as fatigue, exhaustion, shortness of breath, and anemia. Each year the United Kingdom 
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spends over $7 million on drug treatments, pharmaceutical costs and procedures costs $1 to over 
$7 million. In America, costs are unknown, however procedures, pharmaceuticals can start at 
$10,000 a year. Depending on the type of treatment or cause, women with menorrhagia office 
visits can range from 2- 6 times a year. What is known/unknown about the condition is that the 
most common causes include anovulation and abnormal growths in the uterus (polyps or 
fibroids), having condition that increases bleeding. Some symptoms and affects of menorrhagia 
is the constant need to change pads/tampons> 3 hrs or use> 21 pads/ tampons during a period, 
Need of both pads and tampons at the same time, change pads or tampons during the night, pass 
blood clots larger than 1 inch, and also Iron Deficiency Anemia (IDA). Treatment depends on 
cause of bleeding, preferences of the woman, and the desire for children. The usual methods are 
used to treat the condition are Pharmaceuticals including Hormonal birth control, hormonal IUD, 
Implant, Depo-Provera, Antifibrionlytics, NSAIDS, Progestrin, GnRH agonists. If 
pharmaceuticals do not control symptoms, surgery is an option. Surgeries include Endometrial 
ablation and hysterectomies. 
Tranexamic Acid (T A) is a non-hormonal drug that enhances blood clotting is used more 
in Europe than in the US and is proving to be very effective. Increased dissolution of clots is one 
of the causes of DUB. TA is an antifibrnolytic reversibly locks lysine bidning sites on 
plasminogen and thus fibrin degradation and can be promoted as treatment for DUB. There are 
few side effects reported with TA It was first approved by the FDA in 1986 as Cyklokapron and 
has been used to prevent bleeding in patients with hemophilia after tooth extraction. There is 
hope that Tranexamic Acid can effectively treat and improve symptoms of women experiencing 
menorrhagia, either IUD induced or idiopathic. 
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OBJECTIVE 
The objective of this systematic review is to determine if "Tranexamic Acid effectively 
and safely reduces menstrual blood loss in women with Menorrhagia or IUD induced MBL". 
Recent studies have shown other drugs such as desmopression have been effective in reducing 
menstrual blood loss and menorrhagia, however Tranexamic Acid has not previously been tested 
and thus the efficacy of the drug in treating women with menorrhagia/MBL is not known. 
METHODS 
All three studies for this review met the following criteria used for selection of studies. 
The population(s) and/or problems: menorrhagia confirmed through Pictorial Blood Assessment 
Chart (PBAC) >100, completion ofQOL survey, d/c OCP, (-) Pap smear in 12 mo, (-) pelvic 
exam, 20-40 y/o Chinese women. The interventions used in the studies, pts were given 
Tranexamic Acid at different times and different dosages, use after IUD. The comparisons used 
were intranasal Desmopressin, Medroxyprogestrone acetate, Placebo pill. The main outcomes 
are measured: Quality of Life (QOL), reduced MBL, reduced abnormal lab hemostasis, safety 
and efficacy, decreased side effects, well tolerated, safe option for those who want to conceive, 
prevention in Chinese women, reduced dose wi similar effects. The types of studies included: 1 
Crossover RCT, 1 RCT, 1 Double Blind RCT. The articles were selected based on the 
importance of outcomes to the patient (Patient Oriented Evidence that Matters, or POEMS). 
Studies that were included were those that were randomized, controlled and were based on a 
patient oriented outcome. The key words used in searches were Menorrhagia, Tranexamic Acid, 
Transamin. All three articles were written in English, all published in peer reviewed journals and 
chosen and selected using OVID and Medline using Cochrane. InclusionslExclusions criteria 
were that females with menorrhagia, articles had to be randomized in fashion. Articles must be 
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published between 1996- present without prior meta-analysis or systematic reviews. Under these 
criteria, three randomized control trials were identified, and are included in this review. 
Summary of statistics reported or used: P-value, RRR, NNT, ARR, Anova, X2 test. Table 1 
includes the demographics of the three included studies, which were reported. 
Table 1 - Demographics & Characteristics of included studies 
Study Type # Age Inclusion Criteria . Exclusion Criteria WID Intervention 
Pts 
Kouides, Cross 116 Mean (-) Pelvic exam, Ineligible: 80 PO 
2009 over age PAP smear wlin Administer Tranexamic 
(1) RCT 18-50 last 12 mo, screening Acid for 2 
regular periods questionnaire, (-) periods 
q39d, dlc OCP or PBAC > 1 00, Lab 
Rx affecting testing (-) 
coagulation, 
confirmed 
Menorrhagia: 
PBAC> 100, 
abnormalities in 
hemostasis. 
Kriplani, RCT 100 Mean Heavy menstrual Hx ofFibroids, 6 PO 
2006 (2) 36.67 bleeding, OB suspected Tranexamic 
. +1- medical hx was adenomyosis, Acid 2g/day 
7.54 tal,en, endometriosis, or 500mg 
years PBAC>IOO, (-) atypia thyroid QID 
(19- gyn pathology disease, on 
49) hormone therapy, 
unwilling to 
accept medical 
management 
Lin, Doub 175 20-40 Chinese Women Women with 18 PO doses of 
2007 (3) Ie wi regular medical histories Transamin 
Blind menstrual cycles of organic, (1 and 0.5g 
RCT & willing to concomitant BID) 
insert IUD's disease 
influencing 
menstruation, CII 
to T ransamin, 
inta}(e of any Rx 
in month, OCP x 
3mo 
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OUTCOMES MEASURED 
The primary outcomes measured in all three studies had to be POEMs such as improving 
the quality of life those women experiencing menorrhagia, decrease of menstrual blood loss and 
the safety, efficacy and decrease of side effects such as headaches. The outcomes measured 
based on improving quality of life were assessed based on 4 instruments: Health-Related QOL 
instrument, a 14-item tool assessing the number of physically and mentally unhealthy days in the 
past 30 days; Short-Form-36, a 36 item, generic health status survey covering eight health 
concepts that include sub scores of a physical and mental components; Center of Epidemiologic 
Studies Depression Scale, and Modified Rum Menorrhagia Severity Scale, a 13-item scale 
measuring the physical, psychological and social effects of menorrhagia on a woman's health 
status. Change in MBL were estimated by the PBAC recorded at baseline and during a total of 
four menstrual cycles throughout the treatment phase of the studies, as well as the amount of 
soiled tampons/pads recorded included in the PBAC. The safety, efficacy and decreased side 
effects were measured by Student t-test, 2 way Anova, Independent t test. This was based on the 
women's satisfaction with their treatment by subjective increase of symptomatic relief assessed 
by visual analogue scale. 
RESULTS 
The results pertaining to primary outcome were not all presented as dichotomous data. 
Though, all three randomized controlled trials were performed with intention to treat with the 
study participants having menorrhagia and symptoms of menorrhagia. All three studies reported 
Tranexamic Acid as more effective than their placebo or control groups. Table 2 shows results 
from each study. Kripilani trial was presented in dichotomous data. Table 3. Kouides and Lin 
were not. In the Kripinlani study, out of 100 women recruited, six women did not follow the 
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schedule and were excluded from the analysis. 49 patients in the TA acid group and 45 in the 
medroxyprogesterone group as the control. In this study, the mean blood loss with TA based on 
the PBAC score at 3 months of treatment was 58.2%, 61.0%, and 60.3% at 1 st, 2nd, 3rd months of 
treatment, respectively. Reduction with MPA was 54.6%, 51.5% and 57.7% at the three-follow 
ups of treatment. A total of38.8% patients and 33.3% patients ofMPA had a PBAC score of 
<100 at their follow up. 
The Kouides study had a total of 235 participants that met the criterion for menorrhagia 
(PBAC score> 100) with a score of 100-300 range. 116 participants agreed to participate in the 
treatment trial. Treatment was evaluated using a crossover analysis; on average the estimated 
decrease in PBAC from baseline was -64.1 (95% CI= -88.0, -40.3) for IN-DDAVP 
(Desmopression) and -105.7 (95% CI=-130.5, -81.0) for TA. The magnitude of the decrease of 
PBAC score was larger for TA than for IN-DDAVP control group. PBAC scores at baseline at 
end of second treatment period were -21.4% for IN-DDAVP and -51.7% for TA and -19.6% for 
IN-DDVAP and TA -42.6% for those initially randomized to TA. Effect ofTA on QOL 
generally improved based on the four QOL assessment measures. Of the four different QOL 
measures the Ruta menorrhagia severity scale showed the most statistically significant 
improvements. 
A total of 252 eligible women were invited into the Lin study, 57 refused, allowing 195 
subjects to participate. An overall assessment integrating repeated MBL after IUD insertion 
measures in the treatment cycles estimated indicated that 19.9 and 23.8 mllower than that in the 
placebo group (p<0.05). Based on the PBAC assessment, Transamin treated women had a 
significantly lower occurrence of menorrhagia compared with the placebo group. Placebo 
showed 27.69%,58.46%,60.0%, 58.62% Run-in, first cycle, second cycle, third cycle 
Chang, Tranexamic Acid for Menorrhagia 7 
respectively. TXA 2 g treatment showed 36.67%,55.00%,40.35%,26.79% with CI of .25-.86 
and with Ig treatment 24.00%,58%,50%,45.83% and CI of .41-1.54. 
Table 2- Response on duration of bleeding and MBL on PBAC 
Study Time frame Control group TA P- value 95%CI 
Kouides, 6mo: 3 moof Mean of55% Mean of <0.005 19.6-63. 
2009 treatment, 3 mo 60% 
(I) FlU 
Kriplani, 4 cycles Mean of Mean of <0.005 N/A 
2006 (2) 20.5% 47.15% 
Lin, 3 cycles Mean of38% Mean of <0.05 0.25-1.54 
2007 (3) 51% 
As can be seen in Table 2, the percentage reductions from baseline ofPBAC were well reduced 
as compared to control groups with the use of Tranexamic Acid when treating females with 
menorrhagia. All three studies showed results over a time period of more than 3 cycles or months 
resulting in accurate comparisons. In the three trials, all P values were <0.005 showing 
statistically significant results. 
Two out of the three study trials were presented in "continuous data" form therefore 
could not have been converted into "dichotomous" data to analyze the results. The Kripilani 
study however, was in dichotomous form. Through this study, the Control Event Rate (CER) was 
determined as well as the The Experimental Event Rate (EER) to calculate the Relative Risk 
Reduction Rate (RRR) and Absolute Risk Reduction Rate (ARR). The Numbers Needed to Treat 
(NNT) of patients using Tranexamic Acid to improve their QOL and MBL can be determined 
from the Absolute risk reduction from subtracting EER from CER, and using the inverse result of 
11 ARR. The calculated analysis of Outcomes and NNT in order to decrease the mean severity 
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score of patients treated with Tranexamic Acid vs. Medroxyprogestrone Acetate (MP A) for 
Menorrhagia can be seen in Table 3. 
Table 3 - Outcomes and NNT in order to decrease the mean severity score of patients 
treated with Tranexamic Acid vs. Medroxyprogestrone Acetate (MP A) for Meuorrhagia 
CER EER RRR ARR NNT p-value 
.29 .06 0.6- .29 = 0.79 .06-.29= - 1/-0.23 <0.005 
.29 0.23 = -.5 
In the Kouides and Kripilani studies, participants experienced some unfavorable adverse 
effects from Tranexamic Acid and their controls. In the Kouides study, of the 90 patients who 
used either medications 14% (n=13) reported in side effects, 7 to IN-DDVAP and 6 to TA. The 
most commonly reported side effects among those taking both IN-DDAVP and TA were 
headaches as a result oftreatment. Other symptoms of complaint were experiences of transient 
double vision, dizziness and vomiting. Both patients with complaints of dizziness, double vision 
vomiting and headache withdrew from the study. In the Kripilani study, side effects were noted 
in 8 (16.3%) cases with TA and 15 (33.3%) cases with MPA. Like, the Kouides study, the 
majority of patients with adverse effects after taking TA were headaches (6.1%). Other reactions 
included gastrointestinal upsets and giddiness. Of those patients who took MP A, 11.1 % had 
intermittent bleeding, 4.4% for headaches, elI upset, and breast tendemess. One patient had to 
discontinue treatment after having an allergic reaction to T A. 
DISCUSSION 
Based on the three Randomized controlled Trials in this review, the efficacy and safety of 
Tranexamic Acid to reduce MBL with women dealing with menorrhagia has been proven. All 
three trials showed increased improvement with TA compared to placebo or other 
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pharmaceuticals used for menorrhagia prior to TA. Reduction ofMBL to a PBAC of <100 has 
been studied and verified and can now be recommended as the first line therapy to treat women 
with increased blood flow. Xanodyne Pharmaceuticals received approval from the US Food and 
Drug Administration (FDA) for the drug in late November 2009 and Ferring Pharmaceuticals 
acquired Lysteda from Xanodyne Pharmaceuticals on May 10, 2010. Tranexamic acid is the first 
nonhormonal product approved by the FDA for use in treating menorrhagia. 
Women who took tranexamic acid for heavy menstrual bleeding experienced significant 
improvements in quality of life after 3 cycles and improvement of quality of life. Women were 
more able to participate in social, leisure, physical, and social activi ties after taking the 
medication, according to the American Congress of Obstetricians and Gynecologists (ACOG). 
AdVerse reactions to Tranexamic Acid are still present, headaches more commonly, however the 
benefits can outweigh the potential risks. The combination of tranexamic acid and hormonal 
contraceptives can increase the risk for blood clots, stroke, and heart attack. For women who 
can't take hormonal medications, such as those with increased risk of strokes or migraines who 
take estrogen medications, tranexamic acid might be one alternative. Tranexamic acid in the 
form of brand name Lysteda is already being used as a standard, first line treatment for 
menorrhagia and is readily available prescription medication. 
CONCLUSION 
Tranexamic Acid is a safe and effective pharmaceutical to reduce menstrual blood loss in 
women with menorrhagia or IUD induced MBL. This was proven through the numerous 
statistically significant reductions and/or improvements of QOL throughout the three studies 
reviewed. It is another option and options are good for management of a problem that can truly 
be life changing for many women with menorrhagia instead of reverting to hysterectomies. 
Chang, Tranexamic Acid for Menorrhagia 10 
Currently, there are no clinical trial data on the risk of thrombotic events with the concomitant 
use with hormonal contraceptives, women using hormonal contraception should take Lysteda 
only if there is a strong medical need, and if the benefit of treatment will outweigh the potential 
increased risk. Some limitations of the studies were smaller study sizes, doesn't access long term 
safety. Areas for further study could include the effectiveness of subjects with menorrhagiaJIUD 
induced bleeding for long term effects. 
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